Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

被引:6
|
作者
Johns, Andrew C. [1 ]
Yang, Mike [2 ]
Wei, Lai [3 ]
Grogan, Madison [4 ]
Spakowicz, Daniel [3 ,4 ]
Patel, Sandipkumar H. [4 ]
Li, Mingjia [5 ]
Husain, Marium [4 ]
Kendra, Kari L. [4 ]
Otterson, Gregory A. [4 ]
Rosko, Ashley E. [6 ]
Andersen, Barbara L. [7 ]
Carbone, David P. [4 ]
Owen, Dwight H. [4 ]
Presley, Carolyn J. [4 ,8 ]
机构
[1] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Internal Med, Div Med Oncol, Comprehens Canc Ctr, Columbus, OH 43210 USA
[5] Ohio State Univ, Div Hosp Med, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[6] Ohio State Univ, Dept Internal Med, Div Hematol, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA
[8] Ohio State Univ, James Canc Hosp & Solove Res Inst, Comprehens Canc Ctr, 13th Floor Lincoln Tower, 1800 Cannon Dr, Columbus, OH 43210 USA
来源
ONCOLOGIST | 2023年
基金
美国国家卫生研究院;
关键词
checkpoint inhibitor; immunotherapy; toxicity; geriatrics; immune-related adverse events; CHEMOTHERAPY TOXICITY; DEPRESSION; MANAGEMENT; SURVIVAL;
D O I
10.1093/oncolo/oyad097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibitor immunotherapy is revolutionizing cancer care but can lead to significant toxicity. This article describes potential risk factors for immune-related adverse events among older adults. Objectives Immune checkpoint inhibitor immunotherapy (IO) is revolutionizing cancer care but can lead to significant toxicity. This study seeks to describe potential risk factors for immune-related adverse events (irAEs) specifically among older adults. Materials and Methods This was a retrospective study at a single academic comprehensive cancer center based on chart review data abstracted by physicians. For patients aged >= 70 years, frequency, type, and grade of irAEs and their association with baseline patient demographics, comorbidities, mobility, and functional status were characterized using bivariate analysis. Based on those results, multivariable logistic regressions were constructed to model the association between these characteristics with any grade and grade 3 or higher irAEs. Results Data were analyzed for 238 patients aged >= 70 years who received IO for mostly (>= 90%) advanced cancer between 2011 and 2018. Thirty-nine percent of older adults experienced an irAE and 13% experienced one that was grade 3 or higher. In the multivariable analysis, depression was associated with an increased incidence of any grade irAE, while decreased life-space mobility was associated with an increased incidence of grade >= 3 irAEs. Conclusion Most characteristics of special interest among older adults, include fall risk, weight loss, cognitive limitations, and hearing loss, were not associated with irAEs in our study. However, decreased life-space mobility and depression are potential risk factors for IO toxicity among older adults with advanced cancer. Interventions designed to evaluate and mitigate modifiable risk factors for treatment-related toxicity are needed, and the results of this study may be useful for guiding those efforts.
引用
收藏
页码:E625 / E632
页数:8
相关论文
共 50 条
  • [21] Arthritis risk with immune checkpoint inhibitor therapy for cancer
    Pundole, Xerxes
    Abdel-Wahab, Noha
    Suarez-Almazor, Maria E.
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (03) : 293 - 299
  • [22] Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients
    B. Fox
    M. de Toro Carmena
    R. Álvarez Álvarez
    A. Calles Blanco
    C. López López
    S. Pérez Ramírez
    J. Á. Arranz
    M. Martín
    I. Márquez-Rodas
    Clinical and Translational Oncology, 2020, 22 : 555 - 562
  • [23] Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
    To, Kenneth K. W.
    Cho, William C.
    PHARMACEUTICS, 2023, 15 (08)
  • [24] Immune checkpoint inhibitor-related colitis in patients on immunotherapy for cancer
    Sun, Belinda L.
    Elliott, Alexis S.
    Nolte, David
    Sun, Xiaoguang
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 (01) : 17 - 27
  • [25] Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients
    Fox, B.
    de Toro Carmena, M.
    Alvarez Alvarez, R.
    Calles Blanco, A.
    Lopez Lopez, C.
    Perez Ramirez, S.
    Arranz, J. A.
    Martin, M.
    Marquez-Rodas, I
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (04): : 555 - 562
  • [26] Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor
    le Seve, Julien Denis
    Guedon, Alexis F.
    Bordenave, Stephanie
    Agard, Christian
    Connault, Jerome
    Pistorius, Marc-Antoine
    Quereux, Gaelle
    Espitia, Olivier
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (11) : 1049 - 1056
  • [27] Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer
    Li, Xuemeng
    Yang, Fang
    Liu, Baogang
    Ye, Leiguang
    Du, Jingwen
    Fan, Xiaona
    Yu, Yue
    Li, Mengwei
    Bu, Li
    Zhang, Zhuoqi
    Xie, Lili
    Li, Wuquan
    Qi, Jiaqing
    JOURNAL OF IMMUNOTHERAPY, 2024, 47 (06) : 220 - 226
  • [28] Predictors of Toxicity Among Older Adults with Cancer
    Extermann, Martine
    Chetty, Indrin J.
    Brown, Stephen L.
    Al-Jumayli, Mohammed
    Movsas, Benjamin
    SEMINARS IN RADIATION ONCOLOGY, 2022, 32 (02) : 179 - 185
  • [29] Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
    Flora Pirozzi
    Remo Poto
    Luisa Aran
    Alessandra Cuomo
    Maria Rosaria Galdiero
    Giuseppe Spadaro
    Pasquale Abete
    Domenico Bonaduce
    Gianni Marone
    Carlo Gabriele Tocchetti
    Gilda Varricchi
    Valentina Mercurio
    Current Oncology Reports, 2021, 23
  • [30] Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
    Pirozzi, Flora
    Poto, Remo
    Aran, Luisa
    Cuomo, Alessandra
    Galdiero, Maria Rosaria
    Spadaro, Giuseppe
    Abete, Pasquale
    Bonaduce, Domenico
    Marone, Gianni
    Tocchetti, Carlo Gabriele
    Varricchi, Gilda
    Mercurio, Valentina
    CURRENT ONCOLOGY REPORTS, 2021, 23 (02)